Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care…

By Global News Feed

London (UK), February 19, 2024, 7:30 am CET – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announced promising results for its drug candidate VDA-1275 in multiple mouse cancer and human cellular organoid model of solid tumors. VDA-1275 showed statistically significant efficacy as a monotherapy, as well as synergistic effects in combination with two standard-of-care cancer treatments: sorafenib, a kinase inhibitor, and cisplatin, a widely used chemotherapy drug. The study also showed that VDA-1275 induced an immunologic response, inducing anti-tumor macrophages and memory T-cells, and inhibiting tumor-promoting macrophages. The company will present these findings on 28 February, at the Sachs 17th Annual European Life Sciences CEO Forum.

Read the rest here:
Vidac Pharma presents high efficacy in multiple solid tumor models for its next-generation cancer drug candidate and synergy with standard-of-care...

Certa Therapeutics’ FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis

By Global News Feed

MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma), having previously granted Orphan Drug Designation.[1]

View post:
Certa Therapeutics’ FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis

New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses

By Global News Feed

A new global commercial partnership between Boehringer Ingelheim and Sleip will expand access to AI to enhance detection, diagnosis and treatment of lameness in horses. This partnership delivers on the shared commitment of Boehringer and Sleip to deliver innovative solutions that help veterinary professionals continue to advance their profession and improve the care and wellbeing of horses.

Original post:
New collaboration between Boehringer Ingelheim and Sleip leverages AI-technology to help detect lameness in horses

BioCryst Launches ORLADEYO® (berotralstat) in Italy

By Global News Feed

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended ORLADEYO® (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Italy now have access to the first oral, once-daily therapy for the routine prevention of recurrent HAE attacks.

See original here:
BioCryst Launches ORLADEYO® (berotralstat) in Italy

Medigene to Present at Upcoming Conferences

By Global News Feed

Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore.

Read the original post:
Medigene to Present at Upcoming Conferences

Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with…

By Global News Feed

FIBROSARC (NCT04650984) is a Phase III trial evaluating Onfekafusp alfa (L19TNF, also known as Fibromun) plus doxorubicin versus doxorubicin alone as front-line therapy for patients with advanced or metastatic Soft Tissue Sarcoma

See the original post here:
Philogen provides update on pre-planned interim analysis of the Phase III FIBROSARC trial investigating Onfekafusp alfa (L19TNF) in patients with...

→←